Polycystic ovary syndrome (PCOS), also called hyperandrogenic anovulation (HA), or Stein-Leventhal syndrome, is one of the most common endocrine disorders among females. PCOS has a diverse range of causes that are not entirely understood, but there is strong evidence that it is largely a genetic disease.
PCOS produces symptoms in approximately 5% to 10% of women of reproductive age (approximately 12 to 45 years old). It is thought to be one of the leading causes of female subfertility and the most frequent endocrine problem in women of reproductive age. Finding that the ovaries appear polycystic on ultrasound is common, but it is not an absolute requirement in all definitions of the disorder.
The genetic component appears to be inherited in an autosomal dominant fashion with high genetic penetrance but variable expressivity in females; this means that each child has a 50% chance of inheriting the predisposing genetic variant(s) from a parent, and, if a daughter receives the variant(s), the daughter will have the disease to some extent. The genetic variant(s) can be inherited from either the father or the mother, and can be passed along to both sons (who may be asymptomatic carriers or may have symptoms such as early baldness and/or excessive hair) and daughters, who will show signs of PCOS. The allele appears to manifest itself at least partially via heightened androgen levels secreted by ovarian follicletheca cells from women with the allele. The exact gene affected has not yet been identified.
The clinical severity of PCOS symptoms appears to be largely determined by factors such as obesity.
Not all women with PCOS have polycystic ovaries (PCO), nor do all women with ovarian cysts have PCOS; although a pelvic ultrasound is a major diagnostic tool, it is not the only one. The diagnosis is straightforward using the Rotterdam criteria, even when the syndrome is associated with a wide range of symptoms.
Polycystic Ovary as seen on Sonography
Transvaginal ultrasound scan of polycystic ovary
Polycystic Ovary as seen on Sonography
Two definitions are commonly used:
In 1990 a consensus workshop sponsored by the NIH/NICHD suggested that a person has PCOS if she has all of the following:
Other entities are excluded that would cause these.
The Rotterdam definition is wider, including many more women, the most notable ones being women without androgen excess. Critics say that findings obtained from the study of women with androgen excess cannot necessarily be extrapolated to women without androgen excess.
Androgen Excess PCOS Society
In 2006, the Androgen Excess PCOS Society suggested a tightening of the diagnostic criteria to all of:
Gynecologic ultrasonography, specifically looking for small ovarian follicles. These are believed to be the result of disturbed ovarian function with failed ovulation, reflected by the infrequent or absent menstruation that is typical of the condition. In a normal menstrual cycle, one egg is released from a dominant follicle – in essence, a cyst that bursts to release the egg. After ovulation, the follicle remnant is transformed into a progesterone-producing corpus luteum, which shrinks and disappears after approximately 12–14 days. In PCOS, there is a so-called "follicular arrest"; i.e., several follicles develop to a size of 5–7 mm, but not further. No single follicle reaches the preovulatory size (16 mm or more). According to the Rotterdam criteria, 12 or more small follicles should be seen in an ovary on ultrasound examination. More recent research suggests that there should be at least 25 follicles in an ovary to designate it as having polycystic ovarian morphology (PCOM) in women aged 18–35 years. The follicles may be oriented in the periphery, giving the appearance of a 'string of pearls'. If a high resolution transvaginal ultrasonography machine is not available, an ovarian volume of at least 10 ml is regarded as an acceptable definition of having polycystic ovarian morphology instead of follicle count.
Laparoscopic examination may reveal a thickened, smooth, pearl-white outer surface of the ovary. (This would usually be an incidental finding if laparoscopy were performed for some other reason, as it would not be routine to examine the ovaries in this way to confirm a diagnosis of PCOS.)
2-Hour oral glucose tolerance test (GTT) in women with risk factors (obesity, family history, history of gestational diabetes) may indicate impaired glucose tolerance (insulin resistance) in 15–33% of women with PCOS. Frank diabetes can be seen in 65–68% of women with this condition. Insulin resistance can be observed in both normal weight and overweight people, although it is more common in the latter (and in those matching the stricter NIH criteria for diagnosis); 50–80% of people with PCOS may have insulin resistance at some level.
Fasting insulin level or GTT with insulin levels (also called IGTT). Elevated insulin levels have been helpful to predict response to medication and may indicate women needing higher dosages of metformin or the use of a second medication to significantly lower insulin levels. Elevated blood sugar and insulin values do not predict who responds to an insulin-lowering medication, low-glycemic diet, and exercise. Many women with normal levels may benefit from combination therapy. A hypoglycemic response in which the two-hour insulin level is higher and the blood sugar lower than fasting is consistent with insulin resistance. A mathematical derivation known as the HOMAI, calculated from the fasting values in glucose and insulin concentrations, allows a direct and moderately accurate measure of insulin sensitivity (glucose-level x insulin-level/22.5).
Glucose tolerance testing (GTT) instead of fasting glucose can increase diagnosis of increased glucose tolerance and frank diabetes among people with PCOS according to a prospective controlled trial. While fasting glucose levels may remain within normal limits, oral glucose tests revealed that up to 38% of asymptomatic women with PCOS (versus 8.5% in the general population) actually had impaired glucose tolerance, 7.5% of those with frank diabetes according to ADA guidelines.
Polycystic ovaries develop when the ovaries are stimulated to produce excessive amounts of male hormones (androgens), in particular testosterone, by either one or a combination of the following (almost certainly combined with genetic susceptibility):
through high levels of insulin in the blood (hyperinsulinaemia) in women whose ovaries are sensitive to this stimulus
Also, reduced levels of sex-hormone-binding globulin can result in increased free androgens.
The syndrome acquired its most widely used name due to the common sign on ultrasound examination of multiple (poly) ovarian cysts. These "cysts" are actually immature follicles not cysts. The follicles have developed from primordial follicles, but the development has stopped ("arrested") at an early antral stage due to the disturbed ovarian function. The follicles may be oriented along the ovarian periphery, appearing as a 'string of pearls' on ultrasound examination.
Women with PCOS experience an increased frequency of hypothalamic GnRH pulses, which in turn results in an increase in the LH/FSH ratio.
A majority of people with PCOS have insulin resistance and/or are obese. Their elevated insulin levels contribute to or cause the abnormalities seen in the hypothalamic-pituitary-ovarian axis that lead to PCOS. Hyperinsulinemia increases GnRH pulse frequency, LH over FSH dominance, increased ovarian androgen production, decreased follicular maturation, and decreased SHBG binding; all these steps contribute to the development of PCOS. Insulin resistance is a common finding among women with a normal weight as well as overweight women.
In many cases, PCOS is characterised by a complex positive feedback loop of insulin resistance and hyperandrogenism. In most cases, it cannot be determined which (if any) of those two should be regarded causative. Experimental treatment with either antiandrogens or insulin-sensitizing agents improves both hyperandrogenism and insulin resistance.
Adipose tissue possesses aromatase, an enzyme that converts androstenedione to estrone and testosterone to estradiol. The excess of adipose tissue in obese women creates the paradox of having both excess androgens (which are responsible for hirsutism and virilization) and estrogens (which inhibits FSH via negative feedback).
PCOS may be associated with chronic inflammation, with several investigators correlating inflammatory mediators with anovulation and other PCOS symptoms. Similarly, there seems to be a relation between PCOS and increased level of oxidative stress.
It has previously been suggested that the excessive androgen production in PCOS could be caused by a decreased serum level of IGFBP-1, in turn increasing the level of free IGF-I, which stimulates ovarian androgen production, but recent data concludes this mechanism to be unlikely.
PCOS has also been associated with a specific FMR1 sub-genotype. The research suggests that women with heterozygous-normal/low FMR1 have polycystic-like symptoms of excessive follicle-activity and hyperactive ovarian function.
Medical treatment of PCOS is tailored to the woman's goals. In broad terms, these may be considered under four categories:
In each of these areas, there is considerable debate as to the optimal treatment. One of the major reasons for this is the lack of large-scale clinical trials comparing different treatments. Smaller trials tend to be less reliable and hence may produce conflicting results.
General interventions that help to reduce weight or insulin resistance can be beneficial for all these aims, because they address what is believed to be the underlying cause.
As PCOS appears to cause significant emotional distress, appropriate support may be useful.
Where PCOS is associated with overweight or obesity, successful weight loss is the most effective method of restoring normal ovulation/menstruation, but many women find it very difficult to achieve and sustain significant weight loss. A scientific review in 2013 found similar decreases in weight and body composition and improvements in pregnancy rate, menstrual regularity, ovulation, hyperandrogenism, insulin resistance, lipids, and quality of life to occur with weight loss independent of diet composition. Still, a low GI diet, in which a significant part of total carbohydrates are obtained from fruit, vegetables, and whole-grain sources, has resulted in greater menstrual regularity than a macronutrient-matched healthy diet.Vitamin D deficiency may play some role in the development of the metabolic syndrome, so treatment of any such deficiency is indicated.
Not all women with PCOS have difficulty becoming pregnant. For those that do, anovulation or infrequent ovulation is a common cause. Other factors include changed levels of gonadotropins, hyperandrogenemia and hyperinsulinemia. Like women without PCOS, women with PCOS that are ovulating may be infertile due to other causes, such as tubal blockages due to a history of sexually transmitted diseases.
For overweight, anovulatory women with PCOS, weight loss and diet adjustments, especially to reduce the intake of simple carbohydrates, are associated with resumption of natural ovulation.
For those women that after weight loss still are anovulatory or for anovulatory lean women, then the ovulation-inducing medications clomiphene citrate and FSH are the principal treatments used to promote ovulation. Previously, the anti-diabetes medication metformin was recommended treatment for anovulation, but it appears less effective than clomiphene.
Though surgery is not commonly performed, the polycystic ovaries can be treated with a laparoscopic procedure called "ovarian drilling" (puncture of 4–10 small follicles with electrocautery, laser, or biopsy needles), which often results in either resumption of spontaneous ovulations or ovulations after adjuvant treatment with clomiphene or FSH. (Ovarian wedge resection is no longer used as much due to complications such as adhesions and the presence of frequently effective medications.) There are, however, concerns about the long-term effects of ovarian drilling on ovarian function.
When appropriate (e.g., in women of child-bearing age who require contraception), a standard contraceptive pill is frequently effective in reducing hirsutism. A common choice of contraceptive pill is one that contains cyproterone acetate; in the UK, the available brands are Dianette/Diane. Cyproterone acetate is a progestogen with anti-androgen effects that block the action of male hormones that are believed to contribute to acne and the growth of unwanted facial and body hair. On the other hand, progestogens such as norgestrel and levonorgestrel should be avoided due to their androgenic effects.
Other drugs with anti-androgen effects include flutamide, and spironolactone, which can give some improvement in hirsutism. Spironolactone is probably the most-commonly used drug in the US. Metformin can reduce hirsutism, perhaps by reducing insulin resistance, and is often used if there are other features such as insulin resistance, diabetes, or obesity that should also benefit from metformin. Eflornithine (Vaniqa) is a drug that is applied to the skin in cream form, and acts directly on the hair follicles to inhibit hair growth. It is usually applied to the face. Medications that reduce acne by indirect hormonal effects also include ergot dopamine agonists such as bromocriptine. 5-Alpha reductase inhibitors (such as finasteride and dutasteride) may also be used; they work by blocking the conversion of testosterone to dihydrotestosterone (the latter of which responsible for most hair growth alterations and androgenic acne).
Although these agents have shown significant efficacy in clinical trials (for oral contraceptives, in 60–100% of individuals), the reduction in hair growth may not be enough to eliminate the social embarrassment of hirsutism, or the inconvenience of plucking or shaving. Individuals vary in their response to different therapies. It is usually worth trying other drug treatments if one does not work, but drug treatments do not work well for all individuals. For removal of facial hairs, electrolysis, or laser treatments are – at least for some – faster and more efficient alternatives than the above mentioned medical therapies.
Menstrual irregularity and endometrial hyperplasia
If fertility is not the primary aim, then menstruation can usually be regulated with a contraceptive pill. The purpose of regulating menstruation, in essence, is for the woman's convenience, and perhaps her sense of well-being; there is no medical requirement for regular periods, as long as they occur sufficiently often.
If a regular menstrual cycle is not desired, then therapy for an irregular cycle is not necessarily required. Most experts say that, if a menstrual bleed occurs at least every three months, then the endometrium (womb lining) is being shed sufficiently often to prevent an increased risk of endometrial abnormalities or cancer. If menstruation occurs less often or not at all, some form of progestogen replacement is recommended. An alternative is oral progestogen taken at intervals (e.g., every three months) to induce a predictable menstrual bleeding.
There is insufficient evidence to conclude an effect from D-chiro-inositol. Myo-inositol however appears to be effective based on a systematic review.
Dyslipidemia – disorders of lipid metabolism — cholesterol and triglycerides. Women with PCOS show a decreased removal of atherosclerosis-inducing remnants, seemingly independent of insulin resistance/Type II diabetes.
Cardiovascular disease, with a meta-analysis estimating a 2-fold risk of arterial disease for women with PCOS relative to women without PCOS, independent of BMI.
Early diagnosis and treatment may reduce the risk of some of these, such as type 2 diabetes and heart disease.
The prevalence of PCOS depends on the choice of diagnostic criteria. The World Health Organization estimates that it affects 116 million women worldwide as of 2010 (3.4% of women). One community-based prevalence study using the Rotterdam criteria found that about 18% of women had PCOS, and that 70% of them were previously undiagnosed.
One study in the United Kingdom concluded that the risk of PCOS development was higher in lesbian women than in heterosexuals. However, two subsequent studies of women with PCOS have not replicated this finding. Ultrasonographic findings of polycystic ovaries are found in 8-25% of normal women. 14% women on oral contraceptives are found to have polycystic ovaries.
The condition was first described in 1935 by American gynecologists Irving F. Stein, Sr. and Michael L. Leventhal, from whom its original name of Stein-Leventhal syndrome is taken.
The earliest published description of a person with what is now recognized as PCOS was in 1721 in Italy. Cyst-related changes to the ovaries were described in 1844.
Other names for this syndrome include polycystic ovary disease, functional ovarian hyperandrogenism, ovarian hyperthecosis, sclerocystic ovary syndrome, and Stein-Leventhal syndrome. The eponymous last option is the original name; it is now used, if at all, only for the subset of women with all the symptoms of amenorrhea with infertility, hirsutism, and enlarged polycystic ovaries.
Most common names for this disease derive from a typical finding on medical images, called a polycystic ovary. A polycystic ovary has an abnormally large number of developing eggs visible near its surface, looking like many small cysts or a string of pearls.
^Kollmann, M.; Martins, W. P.; Raine-Fenning, N. (2014). "Terms and thresholds for the ultrasound evaluation of the ovaries in women with hyperandrogenic anovulation". Human Reproduction Update20 (3): 463–464. doi:10.1093/humupd/dmu005. ISSN1355-4786.
^"USMLE-Rx" (in English). MedIQ Learning, LLC. 2014. "Stein-Leventhal syndrome, also known as polycystic overy syndrome (PCOS), is a disorder characterized by hirsutism, obesity, and amenorrhea because of luteinizing hormone-resistant cystic ovaries."Missing or empty |url= (help);|accessdate= requires |url= (help)
^ abcdDiamanti-Kandarakis E; Kandarakis H, Legro RS (August 2006). "The role of genes and environment in the etiology of PCOS". Endocrine30 (1): 19–26. doi:10.1385/ENDO:30:1:19. PMID17185788.Cite uses deprecated parameters (help)
^ abGoldenberg N, Glueck C (2008). "Medical therapy in women with polycystic ovary syndrome before and during pregnancy and lactation". Minerva Ginecol60 (1): 63–75. PMID18277353.
^Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (June 2004). "The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population". Journal of Clinical Endocrinology & Metabolism89 (6): 2745–9. doi:10.1210/jc.2003-032046. PMID15181052.
^ abNafiye Y, Sevtap K, Muammer D, Emre O, Senol K, Leyla M (April 2010). "The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome". Fertil. Steril.93 (6): 1864–9. doi:10.1016/j.fertnstert.2008.12.024. PMID19171332.
^Carmina, E; Koyama, T; Chang, L; Stanczyk, FZ; Lobo, RA (December 1992). "Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?". American journal of obstetrics and gynecology167 (6): 1807–12. doi:10.1016/0002-9378(92)91779-a. PMID1471702.Cite uses deprecated parameters (help)
^ abcStrauss JF 3rd (November 2003). "Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome". Annals of the New York Academy of Sciences997: 42–48. doi:10.1196/annals.1290.005. PMID14644808.
^Azziz R (March 2006). "Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature". Journal of Clinical Endocrinology & Metabolism91 (3): 781–785. doi:10.1210/jc.2005-2153. PMID16418211.
^Carmina E (February 2004). "Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines.". Minerva ginecologica56 (1): 1–6. PMID14973405.
^Hart R, Hickey M, Franks S (October 2004). "Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome". Best Practice & Research Clinical Obstetrics & Gynaecology18 (5): 671–83. doi:10.1016/j.bpobgyn.2004.05.001. PMID15380140.
^ abDewailly, D.; Lujan, M. E.; Carmina, E.; Cedars, M. I.; Laven, J.; Norman, R. J.; Escobar-Morreale, H. F. (2013). "Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society". Human Reproduction Update20 (3): 334–352. doi:10.1093/humupd/dmt061. ISSN1355-4786.
^Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA (July 2007). "Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome". Saudi Med J28 (7): 1039–43. PMID17603706.
^Li X, Lin JF (December 2005). "[Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome]". Zhonghua Yi Xue Za Zhi (in Chinese) 85 (46): 3266–71. PMID16409817.
^ abBanaszewska B, Spaczyński RZ, Pelesz M, Pawelczyk L (2003). "Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia". Rocz. Akad. Med. Bialymst.48: 131–4. PMID14737959.
^Dewailly, D.; Andersen, C. Y.; Balen, A.; Broekmans, F.; Dilaver, N.; Fanchin, R.; Griesinger, G.; Kelsey, T. W.; La Marca, A.; Lambalk, C.; Mason, H.; Nelson, S. M.; Visser, J. A.; Wallace, W. H.; Anderson, R. A. (2014). "The physiology and clinical utility of anti-Mullerian hormone in women". Human Reproduction Update20 (3): 370–385. doi:10.1093/humupd/dmt062. ISSN1355-4786.
^Fukuoka M, Yasuda K, Fujiwara H, Kanzaki H, Mori T (1992). "Interactions between interferon gamma, tumour necrosis factor alpha, and interleukin-1 in modulating progesterone and oestradiol production by human luteinized granulosa cells in culture". Hum Reprod7 (10): 1361–4. PMID1291559.
^González F, Rote N, Minium J, Kirwan J (2006). "Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome". J Clin Endocrinol Metab91 (1): 336–40. doi:10.1210/jc.2005-1696. PMID16249279.
^Murri, Mora; Luque-Ramírez, Manual et al. (2013). "Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis". Hum. Reprod. Update19 (3): 268–288. doi:10.1093/humupd/dms059. PMID23303572.
^Kelly, C. J.; Stenton, S. R.; Lashen, H. (2010). "Insulin-like growth factor binding protein-1 in PCOS: a systematic review and meta-analysis". Human Reproduction Update17 (1): 4–16. doi:10.1093/humupd/dmq027. PMID20634211.edit
^Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ (2012). "Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies". Hum. Reprod. Update18 (6): 638–51. doi:10.1093/humupd/dms029. PMID22824735.
^ abMoran, LJ; Ko, H; Misso, M; Marsh, K; Noakes, M; Talbot, M; Frearson, M; Thondan, M; Stepto, N; Teede, HJ (Sep–Oct 2013). "Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines.". Human reproduction update19 (5): 432. doi:10.1093/humupd/dmt015. PMID23727939.Cite uses deprecated parameters (help)
^Leeman L, Acharya U (August 2009). "The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence". J Obstet Gynaecol29 (6): 467–72. doi:10.1080/01443610902829414. PMID19697191.
^Galazis, N; Galazi, M; Atiomo, W (April 2011). "D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review". Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology27 (4): 256–62. doi:10.3109/09513590.2010.538099. PMID21142777.Cite uses deprecated parameters (help)
^Mather KJ, Kwan F, Corenblum B (January 2000). "Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity". Fertility and Sterility73 (1): 150–6. doi:10.1016/S0015-0282(99)00468-9. PMID10632431.
^Unfer V, Zacchè M, Serafini A, Redaelli A, Papaleo E (October 2008). "Treatment of hyperandrogenism and hyperinsulinemia in PCOS patients with essential amino acids. A pilot clinical study". Minerva ginecologica60 (5): 363–8. PMID18854802.
^Moran LJ, Misso ML, Wild RA, Norman RJ (May 2010). "Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis". Hum Reprod Update16 (4): 347–63. doi:10.1093/humupd/dmq001. PMID20159883.
^Barry JA, Kuczmierzyck, AR, Hardiman, PJ (July 2011). "Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis". Hum. Reprod.93 (6): 1948–56. doi:10.1093/humrep/der197. PMID21725075.
^Rocha MP, Maranhão RC, Seydell TM et al. (April 2010). "Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome". Fertil. Steril.93 (6): 1948–56. doi:10.1016/j.fertnstert.2008.12.044. PMID19765700.
^De Groot, P. C. M.; Dekkers, O. M.; Romijn, J. A.; Dieben, S. W. M.; Helmerhorst, F. M. (2011). "PCOS, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-analysis". Human Reproduction Update17 (4): 495–500. doi:10.1093/humupd/dmr001. PMID21335359.edit
^Vos, T; Flaxman, AD; Naghavi, M; Lozano, R; Michaud, C; Ezzati, M; Shibuya, K; Salomon, JA et al. (Dec 15, 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID23245607.|displayauthors= suggested (help)
^Agrawal R, Sharma S, Bekir J, Conway G, Bailey J, Balen AH, Prelevic G. (2004). "Prevalence of polycystic ovaries and polycystic ovary syndrome in lesbian women compared with heterosexual women". J Fertil Steril82 (5): 1352–1357. doi:10.1016/j.fertnstert.2004.04.041. PMID15533359.
^De Sutter P, Dutré T, Vanden Meerschaut F, Stuyver I, Van Maele G, Dhont M (September 2008). "PCOS in lesbian and heterosexual women treated with artificial donor insemination". Reprod. Biomed. Online17 (3): 398–402. doi:10.1016/S1472-6483(10)60224-6. PMID18765011.
^Smith HA, Markovic N, Matthews AK et al. (2011). "A comparison of polycystic ovary syndrome and related factors between lesbian and heterosexual women". Womens Health Issues21 (3): 191–8. doi:10.1016/j.whi.2010.11.001. PMID21310628.
^Polson, DW; Adams, J; Wadsworth, J; Franks, S (Apr 16, 1988). "Polycystic ovaries--a common finding in normal women". Lancet1 (8590): 870–2. PMID2895373.Cite uses deprecated parameters (help)
^ abClayton, RN; Ogden, V; Hodgkinson, J; Worswick, L; Rodin, DA; Dyer, S; Meade, TW (August 1992). "How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?". Clinical endocrinology37 (2): 127–34. doi:10.1111/j.1365-2265.1992.tb02296.x. PMID1395063.Cite uses deprecated parameters (help)
^Farquhar, CM; Birdsall, M; Manning, P; Mitchell, JM; France, JT (February 1994). "The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women". The Australian & New Zealand journal of obstetrics & gynaecology34 (1): 67–72. doi:10.1111/j.1479-828X.1994.tb01041.x. PMID8053879.Cite uses deprecated parameters (help)
^van Santbrink, EJ; Hop, WC; Fauser, BC (March 1997). "Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome". Fertility and Sterility67 (3): 452–8. doi:10.1016/S0015-0282(97)80068-4. PMID9091329.Cite uses deprecated parameters (help)